PT - JOURNAL ARTICLE AU - Gibson, Erin AU - Ramirez, Joel AU - Woods, Lauren Abby AU - Ottoy, Julie AU - Berberian, Stephanie AU - Scott, Christopher J.M. AU - Yhap, Vanessa AU - Gao, Fuqiang AU - Coello, Roberto Duarte AU - Valdes Hernandez, Maria AU - Lang, Anthony E. AU - Tartaglia, Carmela M. AU - Kumar, Sanjeev AU - Binns, Malcolm A. AU - Bartha, Robert AU - Symons, Sean AU - Swartz, Richard H. AU - Masellis, Mario AU - Singh, Navneet AU - Moody, Alan AU - MacIntosh, Bradley J. AU - Wardlaw, Joanna M. AU - Black, Sandra E. AU - ONDRI Investigators, ADNI, CAIN Investigators, colleagues from the Foundation Leducq Transatlantic Network of Excellence AU - Lim, Andrew SP AU - Goubran, Maged TI - segcsvd<sub>WMH</sub>: A convolutional neural network-based tool for quantifying white matter hyperintensities in heterogeneous patient cohorts AID - 10.1101/2024.06.20.24309230 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.20.24309230 4099 - http://medrxiv.org/content/early/2024/07/19/2024.06.20.24309230.short 4100 - http://medrxiv.org/content/early/2024/07/19/2024.06.20.24309230.full AB - White matter hyperintensities (WMH) of presumed vascular origin are an MRI-based biomarker of cerebral small vessel disease (CSVD). WMH are associated with accelerated cognitive decline and increased risk of stroke and dementia, and are commonly observed in aging, vascular cognitive impairment, Alzheimer’s and Parkinson’s disease, and related dementias. The accurate, reliable, and rapid measurement of WMH in large-scale multi-site clinical studies with heterogeneous patient populations remains challenging. The diversity of MRI protocols and image characteristics across different studies as well as the diverse nature of WMH, in terms of their highly variable shape, size, distribution, and underlying pathology, adds additional complexity to this task. Here, we present segcsvdWMH, a novel convolutional neural network-based tool for quantifying WMH. segcsvdWMH is specifically designed for accurate and robust performance when applied to diverse clinical patient datasets. Central to the development of this tool is the curation of a large patient dataset (&gt;700 scans) sourced from seven multi-site studies, encompassing a wide range of clinical populations, WMH burden, and imaging parameters. The performance of segcsvdWMH is evaluated against three widely used WMH segmentation tools, where we demonstrate significantly enhanced accuracy and robustness across a range of challenging conditions and datasets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Canadian Institute of Health Research (CIHR) grants PJT173387 and PJT190220.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Sunnybrook Research Institute gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, which is publicly available upon application and approval at adni.loni.usc.edu. Additionally, it incorporated non-public datasets restricted by privacy agreements. Access to these datasets can be requested from the corresponding author under appropriate conditions.